Idexx Laboratories, Inc.

Idexx’s revenues from its Companion Animal Group segment increased from $439.95 million in Q2 2017 to $507.49 million in Q2 2018.

So far in 2018, Idexx Laboratories (IDXX) stock has generated more than 50.0% returns for investors.

Last big week of earnings kicks off with not a lot to show for it in the market The week of April 30 is an exciting one in terms of earnings, and here are 18 companies we will be watching closely: Monday McDonald’s Corporation (NYSE: MCD) – before the market opens – great year last […]

Since 2012, Quest Diagnostics (DGX) has spent about $1.0 billion on capital investments and $1.0 billion on ten acquisitions to support inorganic growth.

Quest Diagnostics (DGX) expects to witness a 3.0%–5.0% long-term revenue growth rate in the future with earnings growth of 5.0%–9.0%.

Since 2012, Quest Diagnostics (DGX) has been working on a five-point strategy to boost revenue growth and improve quality, service, and efficiency.

With services offered to about half of the total hospitals, Quest Diagnostics (DGX) has become a leading provider of reference testing services in the United States.

Quest Diagnostics (DGX) has projected a run rate savings worth $1.3 billion by the end of 2017. In 2016, it managed to save up to $1.1 billion.

Quest Diagnostics’ (DGX) expanding presence in the independent US laboratory market is worth $27.0 billion.

With around 50.0% of hospitals being served by Quest Diagnostics (DGX), the company has become a leading player in the fragmented US laboratory market.

Valspar (VAL) reports its revenue under two segments, namely: the coatings segment and paints segment.

On June 9, 2016, the top performer within the mid-capitalization space of the iShares U.S. Medical Devices ETF was Idexx Laboratories, which rose by 1.5%.

If Quest Diagnostics succeeds in implementing its five-point business strategy going forward, it should boost the company’s share price and USMV.

Quest Diagnostics has been focusing on developing sales and marketing expertise, increasing esoteric testing, and building relationships with hospitals.

Quest Diagnostics trades at a premium multiple compared to Lab Corp of America and at a big discount compared to peers Davita Healthcare and IDEXX Labs.

In a survey of 22 brokerage companies on April 26, 2016, about 71.4% of the brokers rated LabCorp (LH) a “buy,” while 28.6% rated it a “hold.” None of the brokers rated it a “sell.”

In 1Q16, LabCorp’s (LH) contract research organization business, Covance Drug Development, accounted for 30.7% of the company’s total revenues.

The PBV ratios of Neogen (NEOG), Illumina, Bio-Rad Laboratories (ILMN), and VWR International (VWR) are 6.1x, 14.0x, 1.7x, and 2.7x, respectively.

After Neogen’s (NEOG) fiscal 2Q16 earnings report, NEOG rose by 3.9% to close at $60.24 per share in yesterday’s trade.

Bruker (BRKR) went up by 4.9% on good 3Q15 earnings. The company reported 3Q15 revenues of $396.1 million, a decline of 5.6% compared to 3Q14.

Team Health Holdings (TMH) rose by 10.1% for the week ending October 23, 2015. The stock rose as it announced preliminary numbers for 3Q15.

Neogen (NEOG) has a market cap of $1.84 billion. The company’s YTD (year-to-date) price movement was stable until the last three months of 2015.

The PE multiple is one of the simplest multiples used for valuations. The forward PE ratio for Abbott is ~22x for 2015. It’s ~23.7x for the industry.

Abbott’s net revenue rose by over 3% to $20.2 billion in 2014—compared to $19.6 billion in 2013. The net revenue was ~$19.05 billion in 2012.